• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by ACELYRIN INC.

    5/9/24 8:14:56 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRN alert in real time by email
    DEFA14A 1 d829289ddefa14a.htm DEFA14A DEFA14A

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    ACELYRIN, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    ACELYRIN, INC.

    4149 Liberty Canyon Road

    Agoura Hills, California 91301

     

     

    SUPPLEMENT TO THE PROXY STATEMENT FOR THE

    ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON JUNE 7, 2024

     

    This supplement (this “Supplement”) supplements the definitive proxy statement of ACELYRIN, INC. (the “Company”), filed with the Securities and Exchange Commission (the “SEC”) on April 22, 2024 (the “Proxy Statement”), relating to the Company’s 2024 Annual Meeting of Stockholders to be held on Friday, June 7, 2024 at 9:00 a.m. Pacific Time via live webcast (the “Annual Meeting”).

    Except as supplemented by the information contained herein, this Supplement does not revise or update any of the other information set forth in the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby.

    MANAGEMENT AND BOARD CHANGES

    Chief Executive Officer Succession and Board of Director Changes

    Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company and was appointed as a member of the Board of Directors of the Company (the “Board”). By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024. The Company has entered into a Separation Agreement and Mutual Release with Dr. Lin pursuant to which the Company agreed to provide Dr. Lin with certain benefits, including the following: a lump sum payment equal to approximately 18 months of base salary, approximately 18 months of equity award and restricted stock vesting acceleration, up to 24 months of health insurance premium payments, a lump sum payment equal to a pro-rated portion of her 2024 target bonus, and an extension of the post-termination exercise period of her outstanding stock option awards.

    Ms. Kim’s biographical information may be found under the section titled “Executive Officers” in the Proxy Statement.

    Named Executive Officer Departure

    Effective on May 8, 2024, the Company and Ron Oyston mutually agreed that Mr. Oyston will step down from his position as Chief People Officer, effective August 15, 2024. The Company has entered into a Separation Agreement and Mutual Release with Mr. Oyston pursuant to which the Company agreed to provide Mr. Oyston with certain benefits, including the following: 12 months of each of salary continuation, COBRA health insurance premiums and equity award vesting acceleration, a lump sum payment equal to a pro-rated portion of his 2024 target bonus, and an extension of the post-termination exercise period of his outstanding stock option awards.

    VOTING MATTERS; REVOCABILITY OF PROXIES

    This Supplement does not change the proposals to be acted upon at the Annual Meeting or the recommendations of the Board with respect to such proposals, in each case, as described in the Proxy Statement, and there are no changes to the proxy card previously made available to stockholders.

    If you have already voted by proxy over the telephone or through the internet, or voted by proxy using the proxy card made available to you, then you do not need to take any action unless you wish to change your vote. If you have already voted and wish to change your vote based on any of the information contained in this Supplement or otherwise, you may change your vote or revoke your proxy at any time before it is voted at the Annual Meeting. Important information regarding how to vote your shares of the Company’s common stock and how to revoke or change a proxy already given is available in the Proxy Statement under the caption “Questions and Answers About these Proxy Materials and Voting—Can I change my vote after submitting my proxy?”

    *****


    Important Notice Regarding the Availability of Proxy Materials for the

    Annual Meeting of Stockholders to be held on June 7, 2024, at 9:00 a.m. Pacific Time via live webcast.

    The Notice, the accompanying Proxy Statement, this Supplement and our 2023 Annual Report on Form 10-K

    are available at www.proxyvote.com. Your vote is important. Whether or not you plan to attend the Annual

    Meeting, we urge you to submit your vote in advance via the internet, telephone or mail.

    Get the next $SLRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLRN

    DatePrice TargetRatingAnalyst
    8/14/2024$18.00 → $6.00Buy → Neutral
    H.C. Wainwright
    7/8/2024$13.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$11.00Equal Weight
    Wells Fargo
    12/8/2023$8.00Neutral
    Citigroup
    9/13/2023$19.00Overweight → Equal-Weight
    Morgan Stanley
    9/5/2023$44.00Buy
    H.C. Wainwright
    5/30/2023Overweight
    Morgan Stanley
    5/30/2023$31.00Buy
    Jefferies
    More analyst ratings

    $SLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACELYRIN downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously

    8/14/24 7:48:43 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00

    7/8/24 8:17:02 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on ACELYRIN with a new price target

    Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00

    12/13/23 8:08:18 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Stockholders Approve Merger with ACELYRIN

    SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

    5/13/25 1:00:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

    5/13/25 1:00:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

    ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

    5/6/25 4:30:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:23:20 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:11:54 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cozadd Bruce C

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:11:07 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

    5/23/25 4:15:26 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

    5/23/25 4:01:03 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ACELYRIN INC.

    EFFECT - ACELYRIN, Inc. (0001962918) (Filer)

    5/23/25 12:15:04 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Financials

    Live finance-specific insights

    View All

    ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

    LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close

    3/13/25 7:00:00 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

    2/6/25 4:15:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

    Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

    1/6/25 4:00:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

    Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

    3/27/24 4:01:00 PM ET
    $AVTX
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

    Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.

    2/15/24 4:05:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

    LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN

    12/20/23 4:30:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

    11/14/24 1:28:35 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

    11/12/24 12:13:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ACELYRIN INC.

    SC 13G - ACELYRIN, Inc. (0001962918) (Subject)

    11/4/24 10:56:23 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care